A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Recruiting
Observational Study
Primary Hypercholesterolaemia
Mixed Dyslipidemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,120 (estimated)
- Sponsor
- Daiichi Sankyo · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-f…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients can be enrolled, when they fulfil the following inclusion criteria:
* Written informed consent to participate.
* At least 18 years of age.
* Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid/ FDC wit…
Contacts
Daiichi Sankyo Contact for Clinical Trial Information
908-992-6400
CONTACT